FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2236957533> ?p ?o ?g. }

• W2236957533 endingPage "e0146582" @default.
• W2236957533 startingPage "e0146582" @default.
• W2236957533 abstract "To report globe salvage rates, patient survival and adverse events of ophthalmic artery chemosurgery (OAC) for International Classification of Retinoblastoma (ICRB) group D retinoblastoma (naive and after prior failures).Single institution retrospective review of all Group D eyes treated with OAC from 5/2006-12/2012. Patients were treated according to our previously-published techniques. Primary outcome was globe retention without need for external beam radiotherapy (EBRT). Demographics, prior treatments, OAC agents used, and adverse events were also recorded.112 group D eyes (103 patients) that underwent OAC were included (average follow-up was 34 months, range: 2-110 months). 47 eyes were treatment-naïve, 58 eyes received prior treatments elsewhere, and 7 young infants (7 eyes) underwent our published bridge therapy (single agent intravenous carboplatin) until old enough to undergo OAC. Median number of OAC sessions/eye was 3 (range 1-9). 110/112 eyes received intra-arterial melphalan, but only 31 eyes received melphalan alone. 43 eyes received carboplatin, and 78 eyes received topotecan (never as a single agent). 80/112 eyes received >1 drug over their treatment course, and 39 eyes received all three agents. 24 eyes (16 pretreated, 7 treatment-naïve, 1 bridge) failed treatment and required enucleation during the study period. Enucleation and EBRT were avoided in 88/112 eyes (78.6%; including 40/47 [85.1%] treatment-naïve eyes, 42/58 [72.4%] previously-treated eyes, and 6/7 eyes [85.7%] among bridge patients). By Kaplan-Meier survival analysis, globe salvage rate was 74% at 110 months among all patients, and 85% at 110 months in the treatment-naïve subgroup. Transient grade 3/4 neutropenia was more common in patients receiving OAC bilaterally. No child died of metastatic disease.OAC is effective for curing group D retinoblastoma, achieving rates of globe salvage many times higher than systemic chemotherapy (10-47%), even in eyes that previously failed other treatments. OAC can be performed multiple times, using multiple agents, on one or both eyes of patients." @default.
• W2236957533 created "2016-06-24" @default.
• W2236957533 creator A5000886472 @default.
• W2236957533 creator A5010067150 @default.
• W2236957533 creator A5021697192 @default.
• W2236957533 creator A5044132232 @default.
• W2236957533 creator A5047847872 @default.
• W2236957533 creator A5068118481 @default.
• W2236957533 creator A5089964758 @default.
• W2236957533 date "2016-01-12" @default.
• W2236957533 modified "2023-10-10" @default.
• W2236957533 title "Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma" @default.
• W2236957533 cites W10347719 @default.
• W2236957533 cites W1483659539 @default.
• W2236957533 cites W1857598851 @default.
• W2236957533 cites W1965788876 @default.
• W2236957533 cites W1973662347 @default.
• W2236957533 cites W1979271037 @default.
• W2236957533 cites W1993927965 @default.
• W2236957533 cites W2005507199 @default.
• W2236957533 cites W2006607280 @default.
• W2236957533 cites W2009495972 @default.
• W2236957533 cites W2009934230 @default.
• W2236957533 cites W2016534672 @default.
• W2236957533 cites W2037859122 @default.
• W2236957533 cites W2041046640 @default.
• W2236957533 cites W2045367662 @default.
• W2236957533 cites W2050259067 @default.
• W2236957533 cites W2056435264 @default.
• W2236957533 cites W2059906467 @default.
• W2236957533 cites W2063881466 @default.
• W2236957533 cites W2067611128 @default.
• W2236957533 cites W2069339449 @default.
• W2236957533 cites W2078578521 @default.
• W2236957533 cites W2078839964 @default.
• W2236957533 cites W2089639263 @default.
• W2236957533 cites W2102706108 @default.
• W2236957533 cites W2105363094 @default.
• W2236957533 cites W2107811207 @default.
• W2236957533 cites W2120033395 @default.
• W2236957533 cites W2120363483 @default.
• W2236957533 cites W2124519417 @default.
• W2236957533 cites W2128657225 @default.
• W2236957533 cites W2139470736 @default.
• W2236957533 cites W2140359717 @default.
• W2236957533 cites W2142480746 @default.
• W2236957533 cites W2142665413 @default.
• W2236957533 cites W2145002321 @default.
• W2236957533 cites W2150565224 @default.
• W2236957533 cites W2154962291 @default.
• W2236957533 cites W2157949719 @default.
• W2236957533 cites W2162101139 @default.
• W2236957533 cites W2162201423 @default.
• W2236957533 cites W2166720993 @default.
• W2236957533 cites W2167497727 @default.
• W2236957533 cites W2168914937 @default.
• W2236957533 cites W2322479806 @default.
• W2236957533 cites W4254892493 @default.
• W2236957533 doi "https://doi.org/10.1371/journal.pone.0146582" @default.
• W2236957533 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4710506" @default.
• W2236957533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26756643" @default.
• W2236957533 hasPublicationYear "2016" @default.
• W2236957533 type Work @default.
• W2236957533 sameAs 2236957533 @default.
• W2236957533 citedByCount "101" @default.
• W2236957533 countsByYear W22369575332016 @default.
• W2236957533 countsByYear W22369575332017 @default.
• W2236957533 countsByYear W22369575332018 @default.
• W2236957533 countsByYear W22369575332019 @default.
• W2236957533 countsByYear W22369575332020 @default.
• W2236957533 countsByYear W22369575332021 @default.
• W2236957533 countsByYear W22369575332022 @default.
• W2236957533 countsByYear W22369575332023 @default.
• W2236957533 crossrefType "journal-article" @default.
• W2236957533 hasAuthorship W2236957533A5000886472 @default.
• W2236957533 hasAuthorship W2236957533A5010067150 @default.
• W2236957533 hasAuthorship W2236957533A5021697192 @default.
• W2236957533 hasAuthorship W2236957533A5044132232 @default.
• W2236957533 hasAuthorship W2236957533A5047847872 @default.
• W2236957533 hasAuthorship W2236957533A5068118481 @default.
• W2236957533 hasAuthorship W2236957533A5089964758 @default.
• W2236957533 hasBestOaLocation W22369575331 @default.
• W2236957533 hasConcept C104317684 @default.
• W2236957533 hasConcept C126322002 @default.
• W2236957533 hasConcept C141071460 @default.
• W2236957533 hasConcept C158846371 @default.
• W2236957533 hasConcept C185592680 @default.
• W2236957533 hasConcept C188261085 @default.
• W2236957533 hasConcept C197934379 @default.
• W2236957533 hasConcept C2776577112 @default.
• W2236957533 hasConcept C2776694085 @default.
• W2236957533 hasConcept C2778239845 @default.
• W2236957533 hasConcept C2778684742 @default.
• W2236957533 hasConcept C2780662894 @default.
• W2236957533 hasConcept C2781209748 @default.
• W2236957533 hasConcept C2781451048 @default.
• W2236957533 hasConcept C55493867 @default.
• W2236957533 hasConcept C71924100 @default.

• next